Global Information
회사소개 | 문의 | 위시리스트

Chugai Pharmaceutical Co., Ltd. : 제품 파이프라인 리뷰

Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

리서치사 Global Markets Direct
발행일 2016년 07월 상품 코드 251653
페이지 정보 영문 119 Pages
가격
US $ 1,500 ₩ 1,775,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,551,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,327,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


Chugai Pharmaceutical Co., Ltd. : 제품 파이프라인 리뷰 Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016
발행일 : 2016년 07월 페이지 정보 : 영문 119 Pages

Chugai Pharmaceutical Co., Ltd.는 일본에 본사를 둔 제약 기업으로, 파마슈티컬 제품의 개발 및 상품화를 실시하고 있습니다. 대상 질환 분야는 암, 뼈 및 관절 질환, 신장 질환 등입니다. 또한 바이오 제약과 분자 표적약에 관한 첨단 기술을 이용해 Drug Discovery 및 약제 후보물질 개발을 실시하고 있습니다.

Chugai Pharmaceutical Co., Ltd.의 치료제 개발 파이프라인 현황과 각 개발 단계 비교 분석, 약제 표적, 작용기서, 투여 경로, 분자 종류별 치료제 평가, 최신 기업 뉴스와 발표, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 전해드립니다.

목차

Chugai Pharmaceutical Co., Ltd.의 기본 정보

  • Chugai Pharmaceutical Co., Ltd.의 개요
  • 주요 정보
  • 기업 정보

Chugai Pharmaceutical Co., Ltd. : R&D 개요

  • 주요 치료 범위

Chugai Pharmaceutical Co., Ltd. : 파이프라인 리뷰

  • 개발 단계별 파이프라인 제품
  • 단독요법
  • 파트너 제품
    • 파트너 제품/병용요법 모달리티
  • 아웃 라이선스 제품
    • 아웃 라이선스 제품/병용요법 모달리티

Chugai Pharmaceutical Co., Ltd. : 파이프라인 제품 개요

  • 후기 단계 파이프라인 제품
    • 제3상 제품/병용요법 모달리티
  • 임상 단계 파이프라인 제품
    • 제2상 제품/병용요법 모달리티
    • 제1상 제품/병용요법 모달리티
  • 초기 단계 파이프라인 제품
    • 전임상 제품/병용요법 모달리티
    • 디스커버리 제품/병용요법 모달리티

Chugai Pharmaceutical Co., Ltd. : 치료제 개요

  • ibandronate sodium
  • atezolizumab
  • gantenerumab
  • lebrikizumab
  • obinutuzumab
  • pertuzumab
  • SA-237
  • tocilizumab
  • trastuzumab emtansine
  • basimglurant
  • bevacizumab
  • codrituzumab
  • nemolizumab
  • pictilisib
  • polatuzumab vedotin
  • RG-1577
  • RG-1662
  • RG-7304
  • taselisib
  • Antibody for Colorectal Cancer
  • CH-5036249
  • CH-5164840
  • CH-5449302
  • CH-5451098
  • cVE-199
  • maxacalcitol
  • Monoclonal Antibody for Hepatitis C
  • NA-255
  • PCO-371

Chugai Pharmaceutical Co., Ltd. : 파이프라인 분석

  • 표적별
  • 투여 경로별
  • 분자 종류별
  • 작용기서별

Chugai Pharmaceutical Co., Ltd. : 최신 파이프라인 정보

Chugai Pharmaceutical Co., Ltd. : 개발 휴지중인 프로젝트

Chugai Pharmaceutical Co., Ltd. : 개발이 중지된 파이프라인 제품

  • 개발이 중지된 파이프라인 제품 개요

Chugai Pharmaceutical Co., Ltd. : 기업 이념

Chugai Pharmaceutical Co., Ltd. : 본사 및 자회사 소재지

  • 본사

부록

도표

KSM 15.06.02

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary:

Global Markets Direct's, 'Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review, 2016', provides an overview of the Chugai Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Chugai Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Chugai Pharmaceutical Co., Ltd.
  • The report provides overview of Chugai Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Chugai Pharmaceutical Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Chugai Pharmaceutical Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Chugai Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chugai Pharmaceutical Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chugai Pharmaceutical Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Chugai Pharmaceutical Co., Ltd. Snapshot
    • Chugai Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Chugai Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Chugai Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Chugai Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Chugai Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Chugai Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Chugai Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Chugai Pharmaceutical Co., Ltd. - Drug Profiles
    • atezolizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bevacizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eldecalcitol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gantenerumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lebrikizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • obinutuzumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SA-237
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tocilizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • codrituzumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nemolizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • basmisanil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EOS-789
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PCO-371
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polatuzumab vedotin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RG-7304
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • taselisib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CH-5036249
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CH-5164840
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CH-5449302
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CH-5451098
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CVE-199
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ERY-974
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • maxacalcitol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NA-255
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gMSC-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Chugai Pharmaceutical Co., Ltd. - Pipeline Analysis
    • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Target
    • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
    • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
    • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Chugai Pharmaceutical Co., Ltd. - Recent Pipeline Updates
  • Chugai Pharmaceutical Co., Ltd. - Dormant Projects
  • Chugai Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • nitazoxanide
      • basimglurant
      • bevacizumab
      • hyaluronate sodium
      • NA-808
      • onartuzumab
      • orlistat
      • PA-799
      • parsatuzumab
      • pictilisib
      • RG-7167
      • sembragiline
      • tocilizumab
      • trastuzumab emtansine
  • Chugai Pharmaceutical Co., Ltd. - Company Statement
  • Chugai Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Chugai Pharmaceutical Co., Ltd., Key Information
  • Chugai Pharmaceutical Co., Ltd., Key Facts
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
  • Chugai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
  • Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Chugai Pharmaceutical Co., Ltd. - Phase III, 2016
  • Chugai Pharmaceutical Co., Ltd. - Phase II, 2016
  • Chugai Pharmaceutical Co., Ltd. - Phase I, 2016
  • Chugai Pharmaceutical Co., Ltd. - Preclinical, 2016
  • Chugai Pharmaceutical Co., Ltd. - Discovery, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Target, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Chugai Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2016
  • Chugai Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016
  • Chugai Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016
  • Chugai Pharmaceutical Co., Ltd., Other Locations
  • Chugai Pharmaceutical Co., Ltd., Subsidiaries

List of Figures

  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
  • Chugai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top
전화 문의
F A Q